Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products, including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Endo Pharmaceuticals Solutions, Inc. develops products to treat conditions in urology and endocrinology. The company was founded in 2009 and is headquartered in Malvern, PA.

Chiasma applies its proprietary technology to approved drugs, which not only enables their being switched from injectable to oral, but importantly can result in new indications and/or enhanced absorption. The Company's Transient Permeability Enhancer technology promotes the delivery of drugs to the GI wall and from there to the liver. It is applicable to macromolecules that to-date can be administered only by injection. TPE can be utilized also with small molecules that are already orally available but are poorly absorbed.

Sandoz AG, part of Novartis AG, is a company headquartered in Basel, Switzerland, that develops generic medicines and biosimilars.

Camurus AB operates as a research based pharmaceutical company. The firm engages in the research, development and commercialization of specialty medicines. It provides its products for the treatment of severe and chronic conditions, which includes opioid dependence, pain, cancer and endocrine disorders. The company was founded by Kare Larsson in 1991 and is headquartered in Lund, Sweden.

Sun Pharmaceutical Industries Ltd. engages in manufacturing, developing, and marketing of pharmaceuticals products. It offers tablets, capsules, injectable, inhalers, ointments, creams, and liquids. The company was founded by Dilip Shantilal Shanghvi in 1983 and is headquartered in Mumbai, India.

Indevus Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the acquisition, development and commercialization of products in the fields of urology, gynecology and infectious diseases. The company markets it's product SANCTURA for the treatment of overactive bladder and has compounds in clinical development including SANCTURA XR, NEBIDO, PRO 2000, IP 751, Pagoclone and Aminocandin. It focuses on the clinical development, regulatory review and commercialization of biopharmaceutical products. Indevus Pharmaceuticals was founded in 1988 and is headquartered in Lexington, MA.

GP Pharm is a private Spanish biopharmaceutical firm located in Barcelona area founded in 2000. It is specialized in products for injection mostly within the fields of Oncology and Urology using technological platforms based on Microspheres and Liposomes. The company is working in the complete development of these drugs starting from R&D, pre-clinical and clinical studies and registration until the launch to the market. GP Pharm develops drug delivery formulations for its own and for third parties. The company´s business model is based on four different areas, i.e. R&D, Contract Manufacturing and Contract Development (CDMO), Licensing In & Out and Commercialization. This is affordable by a continuous investment in research and innovative technologies and a wide experienced team of employees most of which are highly trained and possess a bachelor, master or PhD. In addition, GP Pharm’s state of art manufacturing facilities have been widely approved by different Regulatory Agencies –including EU, US or Japan– allowing the firm to be position in a worldwide setting.

Pharmacia & Upjohn Co. LLC, a subsidiary of Pfizer Inc., is a company headquartered in Bingham Farms, MI, that manufactures and supplies pharmaceutical goods.

Lipotec is a well-known worldwide expert in advanced active ingredients for application in cosmetics. As Lubrizol’s Global Center of Expertise for Skin Care, Lipotec™ Active Ingredients researches, develops and produces innovative products – from peptides, biotechnological molecules to botanical extracts and delivery systems. The most known example of their expertise is ARGIRELINE® peptide, the first topical alternative to recognized cosmetic procedures against expression wrinkles.

RadioMedix, Inc. is a private company headquartered in Houston, TX, that engages in research and development of radiopharmaceuticals for diagnosis and therapy of cancer. The firm was founded by Ebrahim S. Delpassand, who is currently the CEO of the company.\nThe company says this about itself: RadioMedix, Inc. is a clinical-stage biotechnology company, and sponsor of the AlphaMedix? trial, based in Houston and Humble, Texas. The company is focused on innovative targeted radiopharmaceuticals for diagnosis, monitoring, and therapy of cancer. RadioMedix is developing radiopharmaceuticals for PET imaging and therapy (alpha- and beta-labeled agents). The company established contract service facilities for academic and industrial partners including a drug discovery center for the early probe development, a pre-clinical core facility for in vitro and in vivo evaluation of radiopharmaceuticals, and cGMP and analytical suite for Phase I-III clinical trials, and the large-scale post-approval commercial manufacturing facility, the Spica Center.

Nanosion Co. Ltd. is a company that conduct the research and development of nanomedicines formulated by nanotechnology (diagnostic agent, therapeutic agent, pain relief agent against cancer).

Advanced Accelerator Applications (AAA), is a European Pharmaceutical Group founded in 2002 by Italian academics as a spin-off of the “European Organization for Nuclear Research” (CERN), Geneva, Switzerland), to develop innovative diagnostic and therapeutic products. AAA’s main focus is in the field of Molecular Imaging and targeted, individualized therapy for the management of patients with serious conditions (Personalized Medicine). AAA is a European leader in the production and commercialization of PET (Positron Emission Tomography) radiopharmaceuticals. PET is a state-of-the-art diagnostic technique that is today mainly used in clinical oncology, cardiology and neurology. AAA also produces a broad range of SPECT products. AAA currently has 17 production and R&D facilities able to manufacture both diagnostics and therapeutic MNM products, and has over 300 employees in 11 countries (France, Italy, UK, Germany, Switzerland, Spain, Poland, Portugal, Israel, United States and Canada).

Wockhardt Ltd. is a Global pharmaceutical and biotechnology company headquartered in Mumbai, India. The company has manufacturing plants in India, UK, Ireland, France and US, and subsidiaries in US, UK, Ireland and France. It is a global company with more than half of its revenue coming from Europe. In 2011–2012 its UK and USA sales alone were US$475 million. It has market presence in emerging markets such as Russia, Brazil, Mexico, Vietnam, Philippines, Nigeria, Kenya, Ghana, Tanzania, Uganda, Nepal, Myanmar, Sri Lanka, Mauritius, Lebanon and Kuwait. The Company has a market capitalisation of over ₹211 billion (US$3.1 billion) and an annual turnover of ₹36 billion (US$520 million). It produces formulations, biopharmaceuticals, nutrition products, vaccines and active pharmaceutical ingredients (APIs). The company employs over 8,600 people globally. Wockhardt Hospitals is a subsidiary of the Wockhardt Group.

Shanghai No.1 Biochem & Pharm Co. Ltd., a subsidiary of Shanghai Pharmaceuticals Holding Co., Ltd., is a Chinese company located in Shanghai. The firm manufactures pharmaceuticals. It was acquired by Shanghai Pharmaceuticals Holding Co., Ltd. from Shanghai Pharmaceutical (Group) Co., Ltd. on February 03, 2010 for $118.49 million.

Novartis Pharma GmbH engages in the production and sale of pharmaceutical products. The firm establishes and operates institutes for the development of medicinal products. It also conducts research and development in the field of pharmacy. The company was founded by Johann Rudolf Geigy-Gemuseus in 1758 and is headquartered in Vienna, Austria.

BCN Peptides is a privately own company completely focused on the cGMP manufacture of Bioactive Peptides for Pharmaceutical and Veterinary applications.

Chengdu Xinnibang Biopharmaceutical Co., Ltd. of Sinopharm Group, established on 2002-06-14, Business scope includes production,Sell ​​freeze-dried powder for injection,Granules,API(Octreotide Acetate),Biological product(Operate within the validity period with the drug production license);Research and development of biological products,Chinese and Western medicine preparations;Sales:Chemical raw materials and products(Free of chemical hazards),chemical reagent,electronic product,Instrumentation,Electromechanical equipment and accessories,glassware;rental service;Technology transfer for pharmaceutical products,consult(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments).